ORGANIZA

Fundación Oncosur

ESCUELA DE PACIENTES CON TUMORES TORÁCICOS

TRATAMIENTO SISTÉMICO EN TUMORES TORÁCICOS

Javier Baena Espinar
Oncología Médica. Hospital 12 de Octubre

COLABORADORES

Lilly · Bristol Myers Squibb · Takeda · asociación española contra el cáncer · Roche · AstraZeneca · El 12Educa · SaludMadrid Hospital Universitario 12 de Octubre

Índice

- ¿Qué es un tratamiento sistémico?
- Quimioterapia
- Terapia antiangiogénica
- Terapias dianas
- Inmunoterapia
- Anticuerpos conjugados

Tratamiento sistémico

Tratamiento para el que se administran sustancias que viajan por el torrente sanguíneo, que llegan y afectan a las células de todo el cuerpo.



Escenario

A Tratamiento principal

B Tratamiento Neoadyuvante

C Tratamiento Adyuvante

D Tratamiento para el cáncer propagado

Características de la célula tumoral



Las características del cáncer ("The hallmarks of cáncer"). (Imagen extraída de Hanahan y Weinberg. Cell. 2011).

Quimioterapia





Quimioterapia: Curiosidades

Quimioterapia

Células sanas también tiene ADN y se replican







Terapia Antiangiogénica

Angiogénesis = Generación de vasos sanguíneos



Terapia Antiangiogénica



Potenciales efectos secundarios:

- Hipertensión
- Sangrado
- Pérdida de proteínas en orina
- Trombosis

Terapia Diana



Existen determinados genes cuya mutación ofrece a la célula tumoral una ventaja adaptativa sobre el tejido sano, favoreciendo no solo su crecimiento local sino el desarrollo de metástasis

Lung cancer management

2005

Chemotherapy

2015

N=17,664 (76% ADC). 6 cancer-associated genes



21% Potentially actionable alterations.

Barlesi , Mazieres – Lancet 2015

Chemotherapy
Targeted therapy (EGFR, ALK)

2020

N=860 ADC. ≥ 300 cancer-associated genes



87% Potentially actionable alterations.

Jordan- Cancer Discovery 2017

Chemotherapy
Immunotherapy
Targeted therapy (multiple)

Response rate, survival

Inmunoterapia



Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The components of the immune system. Accesible desde: http://www.ncbi.nlm.nih.gov/books/NBK27092/

Inmunoterapia



ESCUELA DE PACIENTES CON TUMORES TORÁCICOS







Arens R et al. Trends Immunol. 2020

Inmunoterapia: Toxicidad

Aunque generalmente leves y poco frecuentes, la toxicidad inmunomediada puede existir en cualquier órgano.



Anticuerpos conjugados



Chau CH, et al. Lancet. 2019;394:793-804.



Gracias